Pipeline
The Science
About us
Investors
News

Hit enter to search or ESC to close

Dr David Stamler’s Biotech Showcase Presentation

January 7, 2019 Kerry Rowe

Prana Biotechnology BSC Presntation 20180107 FINAL

Post navigation

Prana Presents at Biotech Showcase

Prana receives Orphan Designation for PBT434 for treatment of MSA

Related Posts

Prana’s Founding Scientist and CSA publishes landmark paper in Nature

October 12, 2014

Prana Comments on Archives of Neurology Publication Which Highlights Critical Role of Brain Metals in Huntington Disease Progression: MGH team publishes data that supports the use of PBT2 in Huntington disease

July 17, 2013

Life Biosciences LLC leads strategic investment of up to A$44.5 million in Prana

December 27, 2018

Recent Posts

New data independently confirms and extends laboratory findings and expands safety profile of ATH434
Alterity Therapeutics meeting with US FDA provides development pathway for ATH434
Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology
Alterity receives a $4.8 million R&D Tax Incentive Refund
European Commission approves Orphan Designation for Alterity’s lead drug candidate

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065